Getting Treatment Just Right - Understanding Direct Oral Anticoagulants

Course overview

Direct oral anticoagulants (DOACs) are the first-line options for the treatment of venous thromboembolism and prevention of stroke and systemic embolism in nonvalvular atrial fibrillation. Since 2009 four DOACs have been FDA approved for these indications, and their use is wide-spread, it is challenging to ensure patient safety as each agent has slightly different pharmacokinetic considerations with its use. Certain clinical situations may favor one DOAC over another. This program will address safety and efficacy with each agent, initial recommendations for dosing and adjustments based on renal considerations, drug interactions, and age and weight. Common risk factors for bleeding will be identified as well as options in support of the management of bleeding, if it should occur, are proposed.